Related Experiment Video
Updated: Nov 28, 2025
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.4K
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
Stefano Ratti1, Annalisa Lonetti2, Matilde Y Follo1
1Department of Biomedical and Neuromotor Sciences, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Cancers
|December 1, 2020
Summary
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) research reveals new subtypes and signaling pathways. Novel targeted therapies offer improved treatment strategies for children with B-ALL.
Area of Science:
- Hematologic Malignancies
- Pediatric Oncology
- Genomics
Background:
- B-cell acute lymphoblastic leukemia (B-ALL) is a common childhood cancer.
- Current treatments for pediatric B-ALL require improvement for better patient outcomes.
- Understanding the molecular complexity of B-ALL is crucial for developing targeted therapies.
Purpose of the Study:
- To review novel B-ALL subtypes identified in childhood.
- To emphasize the role of altered signaling pathways in pediatric B-ALL.
- To discuss emerging targeted therapies for B-ALL subtypes.
Main Methods:
- Genomic landscape analysis using next-generation sequencing.
- Review of current literature on pediatric B-ALL subtypes and pathways.
- Evaluation of targeted therapy efficacy in preclinical and clinical studies.
Main Results:
- Identification of distinct molecular subtypes of pediatric B-ALL.
- Elucidation of key signaling pathways dysregulated in B-ALL.
- Promising results from targeted therapies against specific B-ALL subtypes.
Conclusions:
- Novel B-ALL subtypes and pathways offer new therapeutic targets.
- Targeted therapies show potential to improve outcomes for pediatric B-ALL patients.
- Advancements in genomic sequencing are transforming B-ALL research and treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.2K
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
112
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
112
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
111
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
111
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
92
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
92